CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for Management of Congestive Heart Failure

CTAF
October 29, 2015 10:00AM-4:00PM PT

The California Endowment, Oakland, CA

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting on Thursday, October 29, 2015 to discuss the comparative effectiveness and value of two interventions for patients with congestive heart failure (CHF) – the drug Entresto (a combination of valsartan and sacubitril, Novartis AG), and the CardioMEMS HF System (St. Jude Medical).  The CardioMEMS HF System is a heart failure monitor manufactured by St. Jude Medical and approved by the FDA in May, 2014.  Entresto is a drug for the treatment of heart failure with reduced ejection fraction and was approved by the FDA on July 7, 2015.

Key Dates

Associated Materials

07/09/2015

09/11/2015 – 09/25/2015

Public comments received on the Draft Evidence Report.


09/11/2015

09/17/2015

Research protocol posted to Open Science Framework: https://osf.io/7awvd/